Non-interventional, Observational Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel (ATG) Treatment in Subjects With Either Acromegaly or Neuroendocrine Tumours (NET)
Phase of Trial: Phase IV
Latest Information Update: 16 Jan 2019
Price : $35 *
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly; Neuroendocrine tumours
- Focus Biomarker; Pharmacodynamics
- Acronyms SOPRANo
- Sponsors Ipsen
- 31 Aug 2018 Biomarkers information updated
- 13 Jul 2017 Status changed from active, no longer recruiting to completed.
- 30 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Jul 2017.